SCHEMBL22623635

SCHEMBL22623635

CCCCC1SC(c2ccccc2)(c2ccccc2)C(=O)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 4/20 0.40
▸ MMP9 P14780 4/20 0.40
▸ MMP3 P08254 1/20 0.40
▸ ADAMTS5 Q9UNA0 1/20 0.40
▸ CYP19A1 P11511 1/20 0.37
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ APEX1 P27695 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MMP8 P22894 2/20 0.34
▸ MMP13 P45452 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22623627 0.84 ADAMTS5 (0.42) MMP2MMP9MMP3ADAMTS5CYP19A1
SCHEMBL22623629 0.69 CA2 (0.51) MMP2MMP9MEN1KMT2ACYP1A2
SCHEMBL22623692 0.69 TSHR (0.41) MMP2MMP9MMP3ADAMTS5MEN1
SCHEMBL3250724 0.68 HSD17B10 (0.58) ADAMTS5MEN1KMT2ATSHRKDM4E
SCHEMBL22623637 0.64 KMT2A (0.41) MMP2MMP9MMP3CYP19A1MEN1
SCHEMBL7154238 0.63 KMT2A (0.50) MMP2MMP9MEN1KMT2ACYP1A2
Fenimide SCHEMBL121573 0.63 MMP2 (0.42) MMP2MMP9MMP3MEN1KMT2A
SCHEMBL7102637 0.61 KMT2A (0.47) MMP2MMP9MEN1KMT2ACYP1A2
Water SCHEMBL9798786 0.61 MAOB (0.46) MMP2MMP3ADAMTS5MEN1KMT2A
SCHEMBL645409 0.60 EPHX2 (0.62) ADAMTS5MEN1KMT2ATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20200347045-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2020-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234950-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 MMP2 4644/4885MMP9 4822/4885MMP3 4833/4885
US-20200347045-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 MMP2 4644/4885MMP9 4822/4885MMP3 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback